DK3538134T3 - Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse - Google Patents
Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse Download PDFInfo
- Publication number
- DK3538134T3 DK3538134T3 DK17801644.0T DK17801644T DK3538134T3 DK 3538134 T3 DK3538134 T3 DK 3538134T3 DK 17801644 T DK17801644 T DK 17801644T DK 3538134 T3 DK3538134 T3 DK 3538134T3
- Authority
- DK
- Denmark
- Prior art keywords
- prophylaxation
- trunked
- treatment
- blood coagulation
- von willebrand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16198497 | 2016-11-11 | ||
PCT/EP2017/078840 WO2018087271A1 (en) | 2016-11-11 | 2017-11-10 | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3538134T3 true DK3538134T3 (da) | 2022-02-07 |
Family
ID=57389201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17801644.0T DK3538134T3 (da) | 2016-11-11 | 2017-11-10 | Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse |
Country Status (12)
Country | Link |
---|---|
US (1) | US11890327B2 (da) |
EP (1) | EP3538134B1 (da) |
JP (1) | JP2020504082A (da) |
KR (1) | KR20190073576A (da) |
CN (1) | CN110381986B (da) |
AU (1) | AU2017358865A1 (da) |
CA (1) | CA3043397A1 (da) |
DK (1) | DK3538134T3 (da) |
ES (1) | ES2908008T3 (da) |
SG (2) | SG10201912768YA (da) |
TW (1) | TW201828974A (da) |
WO (1) | WO2018087271A1 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019222682A1 (en) | 2018-05-18 | 2019-11-21 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
CN114072420A (zh) * | 2019-07-04 | 2022-02-18 | 康诺贝林伦瑙有限公司 | 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf) |
WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
KR102647642B1 (ko) * | 2021-05-04 | 2024-03-15 | (주)케어젠 | 혈액 응고 활성을 갖는 펩타이드와 이의 용도 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
CA2205572A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
WO1997003193A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
AT403764B (de) * | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
DE69740154D1 (de) | 1996-04-24 | 2011-05-05 | Univ Michigan | Gegen Inaktivierung resistenter Faktor VIII |
CA2329768C (en) | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
WO2002060951A2 (en) | 2001-01-12 | 2002-08-08 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
DE60234193D1 (de) | 2001-06-14 | 2009-12-10 | Scripps Research Inst | Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen |
AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
CA2484155C (en) | 2002-04-29 | 2015-10-13 | Baxter International Inc. | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
HUE058897T2 (hu) | 2003-02-26 | 2022-09-28 | Nektar Therapeutics | Polimer VIII-as faktor egység konjugátumok |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
DK2298347T3 (da) | 2003-05-06 | 2016-01-11 | Biogen Hemophilia Inc | Koagulationsfaktor kimære proteiner til behandling af en hæmostatisk lidelse |
SI1641823T1 (sl) | 2003-06-12 | 2011-12-30 | Lilly Co Eli | Fuzijski proteini analogni glp-1 |
ES2387028T3 (es) | 2003-12-31 | 2012-09-12 | Merck Patent Gmbh | Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
EP1824988B1 (en) | 2004-11-12 | 2017-04-19 | Bayer HealthCare LLC | Site-directed modification of fviii |
CN101163506B (zh) | 2004-12-27 | 2012-09-26 | 巴克斯特国际公司 | 聚合物-von Willebrand因子偶联物 |
WO2006108590A1 (en) | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation factor viii with enhanced stability and its derivates |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
BRPI0708832A2 (pt) | 2006-03-31 | 2011-06-14 | Baxter Int | construÇço proteinÁcea |
JP5800458B2 (ja) | 2006-06-14 | 2015-10-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質 |
AU2007338298B2 (en) | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
PL2167117T3 (pl) | 2007-06-13 | 2013-01-31 | Csl Behring Gmbh | Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi |
ES2654336T3 (es) | 2008-06-24 | 2018-02-13 | Csl Behring Gmbh | Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada |
US8759293B2 (en) | 2009-11-13 | 2014-06-24 | Grifols Therapeutics Inc. | von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto |
AU2012340501A1 (en) | 2011-12-19 | 2013-07-11 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
NZ626945A (en) | 2012-01-12 | 2016-10-28 | Biogen Ma Inc | Chimeric factor viii polypeptides and uses thereof |
US9458223B2 (en) | 2012-02-15 | 2016-10-04 | Csl Behring Gmbh | Von willebrand factor variants having improved factor VIII binding affinity |
US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
WO2013160005A1 (en) | 2012-04-24 | 2013-10-31 | Novo Nordisk A/S | Pharmaceutical composition suitable for treatment of haemophilia |
PT2882450T (pt) | 2012-07-11 | 2020-02-19 | Bioverativ Therapeutics Inc | Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo |
EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
CN105452289A (zh) * | 2013-06-12 | 2016-03-30 | 诺和诺德股份有限公司 | 适用于治疗血友病的化合物 |
KR20170010895A (ko) | 2014-06-06 | 2017-02-01 | 옥타파마 아게 | 인자 ⅷ 및 폰 빌레브란트 인자 펩티드를 포함하는 조제 |
KR20170026580A (ko) | 2014-07-02 | 2017-03-08 | 씨에스엘 리미티드 | 변형된 폰 빌레브란트 인자 |
RU2017145002A (ru) | 2015-05-22 | 2019-06-24 | Цсл Беринг Ленгнау Аг | Способы получения модифицированного фактора фон виллебранда |
-
2017
- 2017-11-10 TW TW106139051A patent/TW201828974A/zh unknown
- 2017-11-10 EP EP17801644.0A patent/EP3538134B1/en active Active
- 2017-11-10 WO PCT/EP2017/078840 patent/WO2018087271A1/en unknown
- 2017-11-10 KR KR1020197016644A patent/KR20190073576A/ko not_active Application Discontinuation
- 2017-11-10 CA CA3043397A patent/CA3043397A1/en not_active Abandoned
- 2017-11-10 SG SG10201912768YA patent/SG10201912768YA/en unknown
- 2017-11-10 AU AU2017358865A patent/AU2017358865A1/en not_active Abandoned
- 2017-11-10 SG SG11201903954WA patent/SG11201903954WA/en unknown
- 2017-11-10 ES ES17801644T patent/ES2908008T3/es active Active
- 2017-11-10 US US16/349,002 patent/US11890327B2/en active Active
- 2017-11-10 DK DK17801644.0T patent/DK3538134T3/da active
- 2017-11-10 CN CN201780069945.0A patent/CN110381986B/zh active Active
- 2017-11-10 JP JP2019524345A patent/JP2020504082A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201828974A (zh) | 2018-08-16 |
KR20190073576A (ko) | 2019-06-26 |
CN110381986B (zh) | 2023-08-18 |
WO2018087271A1 (en) | 2018-05-17 |
ES2908008T3 (es) | 2022-04-27 |
EP3538134A1 (en) | 2019-09-18 |
US20210268071A1 (en) | 2021-09-02 |
AU2017358865A1 (en) | 2019-05-09 |
SG11201903954WA (en) | 2019-05-30 |
JP2020504082A (ja) | 2020-02-06 |
SG10201912768YA (en) | 2020-02-27 |
US11890327B2 (en) | 2024-02-06 |
CN110381986A (zh) | 2019-10-25 |
EP3538134B1 (en) | 2021-12-29 |
CA3043397A1 (en) | 2018-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3668562T3 (da) | Blodpumpe | |
DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
DK3463465T3 (da) | Exosomer omfattende terapeutiske polypeptider | |
DK4019019T3 (da) | Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling | |
DK3445773T3 (da) | Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf | |
DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
DK3628344T3 (da) | Blodpumpe | |
DK3538134T3 (da) | Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse | |
DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
DK3069739T3 (da) | Blodpumpe | |
DK3341041T3 (da) | Blodstrømspumpe til ventrikulær assistance | |
DK3069738T3 (da) | Blodpumpe | |
DK3244948T3 (da) | Bestemmelse af medikamentdosis | |
DK3302502T3 (da) | Intrapulmonal administration af polynukleotid-agonister af toll-lignende receptor-9 til behandling af lungecancer | |
DK3411393T3 (da) | Administration af manipulerede t-celler til behandling af cancere i centralnervesystemet | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3237045T3 (da) | Indretning til indgivelse af lægemidler | |
DK3391875T3 (da) | Fremgangsmåde til fremstilling af polymer micelle, der indeholder et anionisk lægemiddel | |
DK3258919T3 (da) | Næsepulverformulering til behandling af hypoglykæmi | |
DK3294283T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens | |
MA46284A (fr) | Canule cardiaque | |
DK3199179T3 (da) | Formulering af rekombinant fusionsprotein | |
DK3297656T3 (da) | Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili | |
DK3618845T3 (da) | Peptider til behandling af diabetes | |
DE112017004905A5 (de) | Blutpumpe |